3636
The Ibogaine Dossier
The Ibogaine Dossier

NYU Conference on Ibogaine Nov 5-6, 1999

ICAA graphic<BR>ICAA graphic Amsterdam 1966
ICAA 1996
Amsterdam
The art of Canalizing


Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback
The Ibogaine Dossier

40th International Institute on the Prevention and Treatment of Dependencies

ICAA 1996 AMSTERDAM

Abstracts

Previous abstract/Next abstract

Full paper


NEUROLOGIC AND EEG OBSERVATIONS OF SUBJECTS ADMINISTERED IBOGAINE

Daniel Luciano(1), Ezequiel Jethmal(2) and Edgardo A. Della Sera(3)
(1)Director, Clinical Epilepsy Division, Hospital for Joint Diseases/NYU School of Medicine, Orthopaedic Inst., Room 1229, 301 East 17th Street, New York, NY 10003, USA; (2)Centro Medico Paitilla, Panama City, Republic of Panama; (3)Founding member, Republic of Panama Chapter, American Society of Addiction Medicine (ASAM)

Ibogaine (20-25 mg/kg was orally administered to six subjects and serial neurologic examinations were performed. In three subjects serial EEGs were performed. In all patients, transient ataxia developed. Reality testing remained intact, whether or not hallucinosis occurred. There was no evidence or significant anxiety during treatment. Twenty-four hours after treatment all neurologic examinations were normal. EEGs were normal, awake and/or drowsy, before, during and after treatment. Ibogaine treatment was well-tolerated. There was no evidence of persistent neurologic effects and EEGs remained normal during and after treatment.

Correspondence: Daniel Luciano, MD
NYU Mt Sinai
Comprehensive Epilepsy Center
560 First Avenue, Rivergate - 4th flr
New York, NY 10016

Previous abstract/Next abstract/Index of abstracts

Full paper


Top of page | Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback

© 1996 & 2001
The Ibogaine Dossier